Apr 11, 2025, 08:06 AM by

High Force Research, a leading UK-based provider of specialist chemical R&D and manufacturing services has just appointed Dr. Nathalie Huther as its first-ever Chief Commercial Officer following a recent management buyout. This is a pivotal moment for the company, as it gears up to accelerate growth and deepen its presence in the pharmaceutical, biotech, and specialty chemicals markets. Nathalie brings 15+ years of commercial leadership experience across the chemical and life sciences sectors and will be steering High Force Research’s business development and market expansion strategy.

Apr 11, 2025, 08:06 AM by

Phastar, a global specialist biometrics & data science Contract Research Organization (CRO), has been shortlisted in the ‘CRO Partnership of the Year’ category at the 2025 Citeline Awards for its collaboration with Medicines Development for Global Health (MDGH), a not for profit pharmaceutical company dedicated to the development of affordable medicines for the people who need them most.

Apr 10, 2025, 08:44 AM by

News from Cellistic, which has launched its new Echo™-NK platform to support the production of off-the-shelf Natural Killer cell therapies. The platform offers a cost-effective, GMP-compliant solution for scaling iPSC-derived NK cells, aimed at treating cancers and autoimmune diseases. It also integrates Cellistic’s STAR-CRISPR and Pulse technologies to help speed up development, with several client projects already in progress.

Apr 10, 2025, 08:44 AM by

Cepheid and Oxford Nanopore Technologies announce new collaboration to develop an integrated sequencing workflow to advance infectious disease analysis.

Apr 10, 2025, 08:44 AM by

Vaxess Technologies, Inc., a biotech company developing a novel microarray patch technology to transform home delivery of therapies, today announced it has received an additional $9 million in funding. Investors included RA Capital Management and Engine Ventures.

Apr 10, 2025, 01:00 AM by User Not Found

Bio-IT World | Scientists use prior knowledge to solve new problems, and a novel artificial intelligence (AI) system known as LLM4SD (Large Language Model 4 Scientific Discovery) can likewise synthesize knowledge from existing literature. But the method “goes beyond simply repeating information” by interpreting it and coming up with new hypotheses.

Apr 9, 2025, 08:08 AM by

Sphere Bio, a leading provider of picodroplet-based microfluidics for functional single-cell analysis and isolation, today announced a significant expansion of its APAC distributor network. This development marks a key milestone in the Company’s global commercial strategy to meet growing demand for its next-generation single-cell analysis platforms.

Apr 9, 2025, 08:08 AM by

Our latest press release announces the launch of the RNome Disruptive Research Grant, a new funding opportunity designed to empower scientists exploring the complexities of RNA. We believe this development will be of significant interest to your audience, particularly those working in RNA research, genomics, molecular biology, and related fields. The press release highlights our commitment to advancing RNA science through a competitive grant that will award five researchers $5,000 USD each, along with a one-on-one consultation with our scientific team.

Apr 9, 2025, 01:00 AM by User Not Found

Bio-IT World | At the opening plenary panel at last week’s Bio-IT World Conference & Expo, speakers from pharma, healthcare, and biotech took on the future of AI for pharma and healthcare. Abbie Celniker, Partner, Third Rock Ventures, moderated the conversation which included viewpoints from Per Greisen, President, BioMap; Sofia Guerra, Vice President, Bessemer Venture Partners; Subha Madhavan, Vice President and Head, AI/ML, Quantitative and Digital Sciences, Pfizer; and Sonya Makhni, MD, Medical Director, Mayo Clinic Platform.

Apr 8, 2025, 08:17 AM by

Indivumed is proud to announce major milestones achieved, cementing its position as a leading oncology R&D company.

Apr 8, 2025, 01:00 AM by User Not Found

Bio-IT World| Oral drugs are considered an ideal delivery method for medications because of their noninvasive nature, but they face the challenge of passing through the acidic environment of the upper gastrointestinal (GI) tract. Specifically, the stomach acts as a barrier to anything biological, including oral drugs with biologic content. To overcome this obstacle, a team of researchers at Virginia Tech engineered microbes called bacteriophages, or phages, to infect and reprogram gut bacterial cells to produce and release a sustained flow of a protein-based drug.

Apr 4, 2025, 11:52 AM by User Not Found

Bio-IT World | Yesterday in Boston the Bio-IT World community at the Bio-IT World Conference & Expo honored four new products in the annual Bio-IT World Best of Show competition. New products from Boulder BioComputing, Dantech Corp, The Hyve, and Velsera took top honors.

Apr 3, 2025, 12:56 PM by

Strategic partnership marks launch of early access program offering rapid, long, clonal gene synthesis and high-complexity genes up to 15 kb

Apr 3, 2025, 12:56 PM by

Company prioritizes industry insights on key themes to transform clinical research through innovation in annual Industry Outlook report

Apr 3, 2025, 12:53 PM by

Apr 3, 2025, 12:49 PM by

Israeli startup ProFuse has launched a new drug discovery platform to develop therapies that prevent muscle loss associated with GLP-1 weight-loss drugs, aging, and cancer. The platform uses lab-grown, highly mature human muscle tissues and automated screening to identify promising drug candidates, reducing reliance on animal testing and accelerating development timelines. The company also announced the appointment of veteran life sciences investor Anat Naschitz to its board.

Apr 3, 2025, 12:49 PM by

Apr 3, 2025, 12:47 PM by

Apr 3, 2025, 12:46 PM by

The Chinese pharmaceutical business United Laboratories International offered the Danish manufacturer up to $2 billion for the rights to an experimental medicine. In addition to tiered royalties, Novo Nordisk will make milestone payments of up to $1.8 billion and an upfront payment of $200 million.

Apr 3, 2025, 01:00 AM by User Not Found

Bio-IT World| Weight loss medications are in “skyrocketing” utilization. Yet there have been no comprehensive investigations or studies on the effectiveness and risks of glucagon-like peptide-1 receptor agents (GLP-1RA). Researchers at the WashU Medicine collaborated with the Veterans Affairs (VA) St. Louis Health Care System to examine and evaluate more than two million people with diabetes taking popular weight loss drugs such as Ozempic.